Eine Phase II Studie Zur Beurteilung Der Wirksamkeit Von Rituximab in Der Salvage- Und Hochdosistherapie Mit Autologer Stammzelltransplantation Bei Patienten Mit B-Zell-Non-Hodgkin-Lymphom (Mz-135)

NCT02099292 Phase 2 COMPLETED

The investigator prospectively evaluated the combination of Rituximab and Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) followed by high dose therapy in patients with relapsed/refractory aggressive and indolent lymphoma.

Details

Lead sponsor	Georg Hess, MD
Phase	Phase 2
Status	COMPLETED
Enrolment	103
Start date	2001-05
Completion	2014-03

Conditions

• Relapsed Non-Hodgkin-Lymphoma

Interventions

• Rituximab and DexaBEAM

Primary outcomes

• Progression free survival (PFS) — five years follow up
  PFS at 5 years in patients * completing the entire protocol (PPP) * intention to treat population (IIT)